KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Biocryst Pharmaceuticals (BCRX) Accumulated Depreciation & Amortization (2023 - 2025)

Biocryst Pharmaceuticals' Accumulated Depreciation & Amortization history spans 8 years, with the latest figure at $1.4 million for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 11.48% year-over-year to $1.4 million; the TTM value through Dec 2025 reached $1.4 million, up 11.48%, while the annual FY2025 figure was $1.4 million, 11.48% up from the prior year.
  • Accumulated Depreciation & Amortization reached $1.4 million in Q4 2025 per BCRX's latest filing, up from $1.2 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $1.7 million in Q4 2023 to a low of $1.2 million in Q4 2024.
  • Average Accumulated Depreciation & Amortization over 3 years is $1.4 million, with a median of $1.4 million recorded in 2025.
  • Peak YoY movement for Accumulated Depreciation & Amortization: decreased 24.71% in 2024, then increased 11.48% in 2025.
  • A 3-year view of Accumulated Depreciation & Amortization shows it stood at $1.7 million in 2023, then decreased by 24.71% to $1.2 million in 2024, then grew by 11.48% to $1.4 million in 2025.
  • Per Business Quant, the three most recent readings for BCRX's Accumulated Depreciation & Amortization are $1.4 million (Q4 2025), $1.2 million (Q4 2024), and $1.7 million (Q4 2023).